A Phase II Open-label Single-arm Study to Evaluate the Efficacy and Safety of ADSCs in Subjects With Liver Cirrhosis
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Liver Cirrhosis
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 20 years and 70 years
- Gender
- Both males and females
Description
One milliliter of cell suspension will be injected intrahepatically under sonographic guidance using a gauge-18 needle.
One milliliter of cell suspension will be injected intrahepatically under sonographic guidance using a gauge-18 needle.
Tracking Information
- NCT #
- NCT04088058
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Huang ka Wen, Director National Taiwan University Hospital Principal Investigator: Lee Mi Che, Director Hualien Tzu Chi General Hospital
Get Well Soon